Gadolinium Side Effects and Complications

Send to Friend | Bookmark | Live Chat

Gadolinium has been used for years in the enhancement of MRI images on thousands of patients without a large number of serious adverse events occurring. The US Food and Drug Administration approved Gadolinium for use in MRI procedures in 1988 and since then they have approved five specific Gadolinium based contrast agents for usage in the imaging procedure. Generally, the side effects associated with the injection of Gadolinium are mild. The most common side effects are a mild headache, nausea, and a slight burning sensation at the site of the injection. In a few cases, the patient experiences lightheadedness and low blood pressure.

The serious side effect that occurs with the most frequency after an injection of a Gadolinium based contrast agent is an allergic reaction. The reaction is usually mild, but can quickly turn life-threatening if not treated promptly. The symptoms of an allergic reaction to a Gadolinium based contrast agent include itchy skin, hives, itchy eyes, and a rash. In severe cases, excessive sweating, facial swelling, and shortness of breath may be observed. In some patients, a localized allergic reaction can occur at the site of the injection. This reaction includes slight inflammation and irritation of the blood vessels and the vein subjected to the injection.

A severe side effect attributed to Gadolinium has been observed in patients suffering from advanced kidney disease and kidney failure. The condition is called Nephrogenic Systemic Fibrosis (NSF), also known as Nephrogenic Fibrosing Dermopathy (NFD), and it is considered a very rare condition, with less than 300 cases of the condition confirmed worldwide. The condition is a relatively new one, with the first medical references to the condition appearing in the year 2000. Nephrogenic Systemic Fibrosis affects the skin and internal organs of the afflicted patients, resulting in thick, coarse skin that has the appearance of orange peel. In some cases, the condition has proved to be fatal.

The condition begins with the appearance of reddened or darkened patches on the skin. The patchy areas will start to become hard and tighten, with many patients experiencing severe burning and itching sensations beneath the skin. The thickening of the skin of patients affected by Nephrogenic Systemic Fibrosis restricts the movement of the joints and the soft tissue beneath the affected areas begins to calcify. The condition typically affects the arms, legs, hands, and feet of the patient, though in rare cases it can affect the trunk of the body as well. As the condition advances, it begins to affect the internal organs of the patient, causing them to thicken and scar as well.

Nephrogenic Systemic Fibrosis is a very recently discovered condition and not much is known about it yet. Researchers believe that there is a direct connection between the use of a Gadolinium based contrast agent and the development of Nephrogenic Systemic Fibrosis. The US Food and Drug Administration has issued a public health advisory warning of the dangers of the injectable contrast agents and experts are recommending that individuals with advanced kidney disease or kidney failure should avoid these contrast agents if possible.

Main Gadolinium Content Sections

Gadolinium

Nephrogenic Systemic Fibrosis (NSF)

Nephrogenic Fibrosing Dermopathy (NFD)

Related Contents - Gadolinium, Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

What Is Gadolinium?

Gadolinium and Magnetic Resonance Imaging (MRI)

Gadolinium and MRI Safety Guidelines

>> Gadolinium Side Effects and Complications

Issues with MRI Contrast Agents

Gadolinium Based Contrast Agents Used With Magnetic Resonance Imaging

Gadolinium and NSF/NFD

What Is Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy?

Does Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis?

Nephrogenic Systemic Fibrosis Associated With Agents Containing Gadolinium

Devastating Condition Called Nephrogenic Systemic Fibrosis Subject Of Alert By The FDA

The Theory Behind How Gadolinium Based Contrast Agents Cause Nephrogenic Systemic Fibrosis

Nephrogenic Systemic Fibrosis and MRI Contrast Agents

Symptoms and Signs of Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Treatment Options For Nephrogenic Systemic Fibrosis / Nephrogenic Fibrosing Dermopathy

Dialysis May Prevent Nephrogenic Systemic Fibrosis

Risk For Nephrogenic Systemic Fibrosis in Patients With Advanced Kidney Disease

Gadolinium Based MRI Contrast Agent Section

Magnevist MRI NSF

Gadolinium Based Contrast Agent - Magnevist

Magnevist and Nephrogenic Systemic Fibrosis

MultiHance MRI NSF

Gadolinium Based Contrast Agent – MultiHance

Omniscan MRI NSF

OptiMARK MRI NSF

Prohance MRI NSF

Related Websites & Recent Gadolinium Studies

5/23/07 - FDA Press Release

2/07/07 - Study Links Gadolinium treatment to NSF

1/25/07 - MRI Contrast Agent Linked to Rare Disease

1/15/07 - Dialysis to Prevent NSF After Gadolinium Treatment

Do I have a Gadolinium Lawsuit?

The Products Liability Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Gadolinium lawsuits. We are handling individual litigation nationwide and currently accepting new Gadolinium side effect cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field